Young children with acute lymphoblastic leukemia (ALL) appeared to experience anxiety around medical procedures in their first 1.5 years after diagnosis that seemed to decrease over time, according to ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

HealthDay News — Overall cancer mortality rates declined from 2001 through 2022, while cancer incidence rates decreased from 2001 through 2013 and stabilized through 2021, according to the 2024 Annual ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Registered nurse shift length and skill level mix in the previous 7 days influence sickness-related absences in nurse and nursing support staff.

The decision to choose systemic adjuvant therapy warrants careful discussion on its benefits and risks,” researchers wrote.

This study found that most patients with head and neck cancer return to work after treatment, with advanced tumor stage and greater fatigue being mediating factors.

Two studies examining relationships between measures of kidney function and adverse events after platinum-based chemotherapy were presented as late-breaking abstracts at the National Kidney Foundation ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

To develop the combined model, the researchers integrated the imaging-derived radiomics score from the best-performing radiomics model (random forest) with the clinical model.

The cohort study included more than a quarter million men with prostate cancer from routine clinical practice.

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.